Associated tags: Arginine, Therapy, European Medicines Agency, Homocystinuria, DSM-IV codes, Pharmaceutical industry, Patient, Engineering, Enzyme, Arginase
Locations: LONDON, TEXAS, NEW YORK, EUROPE, MASSACHUSETTS, UNITED KINGDOM, UK
Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
Key Points:
- Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
- A replay of the webcast will be available through the Company's website for 30 days thereafter.
- Aeglea BioTherapeutics is a late clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options.
- Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families.
Retrieved on:
Thursday, December 17, 2020
AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ --Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of Alison Lawton to its Board of Directors.
Key Points:
- AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ --Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of Alison Lawton to its Board of Directors.
- "We are pleased to welcome Alison to the Aeglea Board at this pivotal stage of the company's growth.
- "This is an exciting time to be joining Aeglea with a late-stage human enzyme therapeutic being investigated to treat Arginase 1 Deficiency and a second, clinic-ready program for Homocystinuria," said Ms. Lawton.
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases.
Retrieved on:
Tuesday, November 24, 2020
AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ --Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore.
Key Points:
- AUSTIN, Texas, Nov. 24, 2020 /PRNewswire/ --Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced updated timing for its Fireside Chat presentation at an upcoming investor conference hosted by Evercore.
- Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
- An archived version of the webcasts will also be available through the Company's website for a limited time following the conference.
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases.
Retrieved on:
Tuesday, November 17, 2020
Conference Date:November 30 - December 3, 2020
Key Points:
- Conference Date:November 30 - December 3, 2020
To access the live and archived webcasts, visit the Presentations & Events section of the Company's website.
- Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
- An archived version of the webcasts will also be available through the Company's website for a limited time following the conferences.
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases.
Additionally, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug Designation for ACN00177 for the treatment of Homocystinuria in the European Union.
Key Points:
- Additionally, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending Orphan Drug Designation for ACN00177 for the treatment of Homocystinuria in the European Union.
- ACN00177 is a novel engineered human enzyme therapy designed to lower the total level of homocysteine in the plasma.
- Aeglea is developing ACN00177 for the treatment of patients with cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria.
- The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020.
Retrieved on:
Wednesday, September 2, 2020
Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
Key Points:
- Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
- Ch.B., Ph.D., Aegleas president and chief executive officer and Charles N. York II, M.B.A., Aegleas chief financial officer
Participants: Anthony G. Quinn, M.B.
- The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020.
- Aeglea has an active discovery platform, with the most advanced program for Cystinuria.
AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020.
Key Points:
- AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in two presentations at the World Orphan Drug Congress USA 2020 being held virtually August 24-27, 2020.
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases.
- The Company initiated a Phase 1/2 clinical trial of ACN00177 for the treatment of Homocystinuria in the second quarter of 2020.
- Aeglea has an active discovery platform, with the most advanced program for Cystinuria.
AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today reported its second quarter 2020 financial results, and provided recent corporate and program highlights.
Key Points:
- AUSTIN, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today reported its second quarter 2020 financial results, and provided recent corporate and program highlights.
- Research and development expenses totaled $16.9 million for the second quarter of 2020 and $14.8 million for the second quarter of 2019.
- General and administrative expenses totaled $4.7 million for the second quarter of 2020 and $3.8 million for the second quarter of 2019.
- The Company initiated a Phase 1/2 trial in the second quarter of 2020 and continues patient identification and administrative activities.
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases.
Key Points:
- Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases.
- Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations.
- The Company received approval of its Clinical Trial Application (CTA) for ACN00177 for the treatment of Homocystinuria by the United Kingdoms Medicines and Healthcare Products Regulatory Agency (MHRA).
- Aeglea has an active discovery platform, with the most advanced program for Cystinuria.
As previously announced, the annual meeting will be held onMonday, June 8, 2020at9:00 a.m. Central Time.
Key Points:
- As previously announced, the annual meeting will be held onMonday, June 8, 2020at9:00 a.m. Central Time.
- To be admitted to the annual meeting at www.virtualshareholdermeeting.com/AGLE2020 , stockholders must enter the control number found on their proxy card, voting instruction form or notice previously received.
- Further information regarding this change to the location of the annual meeting can be found in the supplemental proxy materials filed by Aeglea with theSecurities and Exchange CommissiononMay 28, 2020.
- Examples of forward-looking statements include, among others, statements we make regarding our plans to hold the 2020 annual meeting of stockholders.
